Alexander M. Castellino, PhD
September 10, 2019
Treatment for chronic lymphocytic leukemia (CLL) is more patient-friendly now with the newer oral targeted therapies that have appeared within the last three years, Jennifer A. Woyach, MD, from the Ohio State University Comprehensive Cancer Center in Columbus, Ohio, told Medscape Medical News. She was referring to the oral agents, ibrutinib (Imbruvica, Pharmacyclics/Janssen) and venetoclax (Venclexta, AbbVie/Genentech) that have rapidly changed the treatment landscape for CLL.
"These agents are extremely exciting, and a high interest right now is in determining how best to use them, whether it is in combination versus sequential and intermittent versus continuous," Woyach told Medscape Medical News.